Epi+Gen CHD™: A NextGen test for improved three-year coronary heart disease risk assessment
Epi+Gen CHD™ takes a completely new approach to coronary heart disease risk assessment by combining DNA testing of genetic and epigenetic biomarkers with artificial intelligence-based analysis to generate personalized risk profiles for each patient. This evidence-based test is based on patent-pending and proprietary technologies.
NextGen Technology Allows Better Prevention of Coronary Heart Disease
Every 40 seconds
someone has a heart attack.
655,000 Americans
are killed by heart disease each year.
600,000+ people
each year experience their first heart attack.
$219 billion
is the yearly cost of heart disease in healthcare and lost productivity.
Early risk screening can drastically reduce the chances of a life altering cardiac event
However, primary care clinicians must still rely on crude tools to understand which of their patients are at high risk. Current risk screening methods have several limitations:
Lacks flexibility
Traditional tests require an in-person clinic visit. With primary care visits down especially due to COVID-19, many patients are cancelling their routine screening.
Low sensitivity
Current lipid-based tests have low sensitivity, especially for women.
Radiation
Coronary calcium screening can expose patients to potentially harmful ionizing radiation.
Broad timelines
Current tools use long-term (10-year) windows that do not capture near term risk.
